1-20 of 39
Othman Al-Sawaf
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Othman Al-Sawaf, Benjamin N. Locher, Friederike Christen, Sandra Robrecht, Can Zhang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl Anton Kreuzer, Coral Fustero, Raphael Hablesreiter, John F. Seymour, Piers Blombery, Lars Bullinger, Brenda Chyla, Hyun Yong Jin, Yanwen Jiang, Stephan Stilgenbauer, Barbara F. Eichhorst, Michael J. Hallek, Kirsten Fischer, Frederik Damm
Journal: Blood
Blood (2024) 144 (Supplement 1): 4613.
https://doi.org/10.1182/blood-2024-208727
Published: 2024
Journal Articles

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

Florian Simon, Rudy Ligtvoet, Moritz Fürstenau, Petra Langerbeins, Anna Maria Fink, Julia Von Tresckow, Paula Cramer, Christian Bjørn Poulsen, Thomas Illmer, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Liliya Sivcheva, Javier Loscertales, Kathleen Jentsch-Ullrich, Holger F. Hebart, Mark-David Levin, Caspar Da Cunha-Bang, Nadine Kutsch, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Sandra Robrecht, Arnon P. Kater, Carsten Utoft Niemann, Kirsten Fischer, Michael Hallek, Barbara F. Eichhorst, Othman Al-Sawaf
Journal: Blood
Blood (2024) 144 (Supplement 1): 6799.
https://doi.org/10.1182/blood-2024-203673
Published: 2024
Journal Articles

Polyfunctional Effector PD-1 + CD8 + T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models

Elisa Ten Hacken, Johan Gustafsson, Chiara Tomasoni, Gabriela Brunsting Hoffmann, Kayla Cruz, Wesley S Lu, Shuqiang Li, Nicholas Haradhvala, Connor Johnson, Stephanie Deng, Xia Bu, Donna S. Neuberg, Othman Al-Sawaf, Barbara F. Eichhorst, Clare Sun, Erin M. Parry, Gordon J. Freeman, Gad Getz, Catherine J. Wu
Journal: Blood
Blood (2024) 144 (Supplement 1): 761.
https://doi.org/10.1182/blood-2024-201006
Published: 2024
Journal Articles

Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial

Ellinor Goergen, Sandra Robrecht, Adam Giza, Can Zhang, Pascal Nieper, Florian Simon, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf, Nadine Kutsch, Anna Maria Fink, Ursula Vehling-Kaiser, Lothar Müller, Michael J. Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Beate Stauch, Clemens-Martin Wendtner, Eugen Tausch, Christof Schneider, Kirsten Fischer, Stephan Stilgenbauer, Barbara F. Eichhorst, Michael Hallek, Petra Langerbeins
Journal: Blood
Blood (2024) 144 (Supplement 1): 1859.
https://doi.org/10.1182/blood-2024-200903
Published: 2024
Journal Articles

Venetoclax May Overcome the Prognostic Disadvantage of Short Telomeres Regarding Progression Free Survival in Previously Untreated CLL Patients with Coexisting Conditions: A Study By the German CLL Study Group (GCLLSG)

Lukas Peter Frenzel, Laura Beckmann, Sandra Robrecht, Can Zhang, Anna Maria Fink, Othman Al-Sawaf, Christof Schneider, Brenda Chyla, Hyun Yong Jin, Yanwen Jiang, Tim H. H. Brummendorf, Michael Hallek, Barbara F. Eichhorst, Kirsten Fischer, Fabian Beier, Susanne Isfort
Journal: Blood
Blood (2024) 144 (Supplement 1): 3250.
https://doi.org/10.1182/blood-2024-200075
Published: 2024
Journal Articles

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Clinical Trials & Observations
Othman Al-Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Liliya Sivchev, Carsten Utoft Niemann, Anthony Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Beenish S. Manzoor, Dureshahwar Jawaid, Nnadozie Emechebe, Jacob Devine, Michelle Boyer, Eva D. Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Journal: Blood
Blood (2024) 144 (18): 1924–1935.
https://doi.org/10.1182/blood.2024024631
Published: 2024
Includes: Supplemental data
Journal Articles

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Clinical Trials & Observations
Moritz Fürstenau, Adam Giza, Jonathan Weiss, Fanni Kleinert, Sandra Robrecht, Fabian Franzen, Janina Stumpf, Petra Langerbeins, Othman Al-Sawaf, Florian Simon, Anna-Maria Fink, Christof Schneider, Eugen Tausch, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Kirsten Fischer, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2024) 144 (3): 272–282.
https://doi.org/10.1182/blood.2023022730
Published: 2024
Includes: Supplemental data
Journal Articles

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Clinical Trials & Observations
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna Maria Fink, Moritz Fürstenau, Nadine Kutsch, Florian Simon, Valentin Goede, Manuela Hoechstetter, Carsten Utoft Niemann, Caspar da Cunha-Bang, Arnon Kater, Julie Dubois, Michael Gregor, Philipp Bernhard Staber, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Barbara Eichhorst, Kirsten Fischer, Michael Hallek
Journal: Blood
Blood (2024) 143 (25): 2588–2598.
https://doi.org/10.1182/blood.2023022564
Published: 2024
Includes: Supplemental data
Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Othman Al-Sawaf, Moritz Fürstenau, Adam Giza, Sandra Robrecht, Julia Von Tresckow, Anna Maria Fink, Florian Simon, Eugen Tausch, Christof Schneider, Liliya Sivcheva, Anthony Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah R. Kilfoyle, Gunnar Juliusson, Caspar Da Cunha-Bang, Thomas Illmer, Michael Gregor, Patrick Thornton, Ann Janssens, Tamar Tadmor, Vesa Lindström, Philipp Bernhard Staber, Mark-David Levin, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Stephan Stilgenbauer, Arnon P. Kater, Carsten Utoft Niemann, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek
Journal: Blood
Blood (2023) 142 (Supplement 1): 4639.
https://doi.org/10.1182/blood-2023-188827
Published: 2023
Journal Articles

Tislelizumab Plus Zanubrutinib in Patients with Richter Transformation: Primary Endpoint Analysis of the Prospective, Multi-Center, Phase-II RT1 Trial of the German CLL Study Group

Othman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht, Janina Stumpf, Anna Maria Fink, Eugen Tausch, Christof Schneider, Sebastian Böttcher, Martin Mikusko, Matthias Ritgen, Johannes Schetelig, Julia Von Tresckow, Ursula Vehling-Kaiser, Clemens-Martin Wendtner, Kirsten Fischer, Karl Anton Kreuzer, Stephan Stilgenbauer, Philipp Bernhard Staber, Carsten Utoft Niemann, Michael Hallek, Barbara F. Eichhorst
Journal: Blood
Blood (2023) 142 (Supplement 1): 204.
https://doi.org/10.1182/blood-2023-188705
Published: 2023
Journal Articles

Outcomes and Treatment Sequences of Therapies with BCL2- and BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): An Analysis of Patient Data within the German CLL Study Group (GCLLSG) Registry

Nadine Kutsch, Rudy Ligtvoet, Sandra Robrecht, Hartmut Linde, Thomas Illmer, Steffen Doerfel, Joerg Lipke, Ali Aldaoud, Rudolf Schlag, Jolanta Dengler, Othman Al-Sawaf, Petra Langerbeins, Paula Cramer, Barbara F. Eichhorst, Michael Hallek, Kirsten Fischer, Anna Maria Fink
Journal: Blood
Blood (2023) 142 (Supplement 1): 4644.
https://doi.org/10.1182/blood-2023-185741
Published: 2023
Journal Articles

Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group

Florian Simon, Rudy Ligtvoet, Sandra Robrecht, Paula Cramer, Nadine Kutsch, Moritz Furstenau, Valentin Goede, Julia Von Tresckow, Petra Langerbeins, Anna-Maria Fink, Henriette Huber, Eugen Tausch, Christof Schneider, Clemens-Martin Wendtner, Matthias Ritgen, Martin Dreyling, Lothar Müller, Lutz Jacobasch, Werner Heinz, Ursula Vehling-Kaiser, Liliya Sivcheva, Sebastian Böttcher, Peter Dreger, Thomas Illmer, Michael Gregor, Philipp Bernhard Staber, Stephan Stilgenbauer, Carsten Utoft Niemann, Arnon P. Kater, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek, Othman Al-Sawaf
Journal: Blood
Blood (2023) 142 (Supplement 1): 1901.
https://doi.org/10.1182/blood-2023-178597
Published: 2023
Journal Articles

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial

Moritz Furstenau, Adam Giza, Anna-Maria Fink, Sandra Robrecht, Jonathan Weiss, Fanni Kleinert, Christof Schneider, Eugen Tausch, Kirsten Fischer, Petra Langerbeins, Othman Al-Sawaf, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara F. Eichhorst, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2023) 142 (Supplement 1): 203.
https://doi.org/10.1182/blood-2023-173708
Published: 2023
Journal Articles

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

Moritz Furstenau, Adam Giza, Christof Schneider, Eugen Tausch, Sandra Robrecht, Matthias Ritgen, Jörg Bittenbring, Holger F. Hebart, Björn Schöttker, Anna Lena Illert, Ullrich Graeven, Andrea Stoltefuss, Bernhard Heinrich, Robert Eckert, Anna-Maria Fink, Janina Stumpf, Florian Simon, Kirsten Fischer, Othman Al-Sawaf, Petra Langerbeins, Fanni Kleinert, Jonathan Weiss, Karl-Anton Kreuzer, Anke Schilhabel, Monika Brüggemann, Barbara F. Eichhorst, Stephan Stilgenbauer, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2023) 142 (Supplement 1): 1897.
https://doi.org/10.1182/blood-2023-173707
Published: 2023
Journal Articles

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

Clinical Trials & Observations
Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten U. Niemann, Michael Kneba, Othman Al-Sawaf, Karl-Anton Kreuzer, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2023) 142 (11): 961–972.
https://doi.org/10.1182/blood.2023020013
Published: 2023
Includes: Supplemental data
Journal Articles

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

Clinical Trials & Observations
Petra Langerbeins, Can Zhang, Sandra Robrecht, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf, Julia von Tresckow, Anna-Maria Fink, Karl-Anton Kreuzer, Ursula Vehling-Kaiser, Eugen Tausch, Lothar Müller, Michael Josef Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens-Martin Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Journal: Blood
Blood (2022) 139 (2): 177–187.
https://doi.org/10.1182/blood.2021010845
Published: 2022
Includes: Supplemental data
Journal Articles

TP53 mutations in CLL: does frequency matter?

Othman Al-Sawaf, Kirsten Fischer
Journal: Blood
Blood (2021) 138 (25): 2600–2601.
https://doi.org/10.1182/blood.2021012343
Published: 2021
Journal Articles

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations

Clinical Trials & Observations
Paula Cramer, Eugen Tausch, Julia von Tresckow, Adam Giza, Sandra Robrecht, Christof Schneider, Moritz Fürstenau, Petra Langerbeins, Othman Al-Sawaf, Benedikt W. Pelzer, Anna Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Barbara Eichhorst, Michael Kneba, Stephan Stilgenbauer, Michael Hallek
Journal: Blood
Blood (2021) 138 (19): 1805–1816.
https://doi.org/10.1182/blood.2020010484
Published: 2021
Includes: Supplemental data
Journal Articles

ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia

Matthew S. Davids, Kirsten Fischer, Sandra Robrecht, Can Zhang, Inhye E. Ahn, Michele Porro Lurà, Wendy Sinai, Brenda Chyla, Kavita Sail, John Pesko, Madhavi Pai, Viktor Komlosi, Michael Hallek, Jennifer R. Brown, Othman Al-Sawaf
Journal: Blood
Blood (2021) 138 (Supplement 1): 2634.
https://doi.org/10.1182/blood-2021-153033
Published: 2021
Journal Articles

Pooled Analysis of First-Line Treatment with Targeted Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Aged 80 Years and Older

Florian Simon, Adam Giza, Sandra Robrecht, Anna-Maria Fink, Paula Cramer, Julia Von Tresckow, Moritz Fürstenau, Valentin Goede, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Clemens-Martin Wendtner, Barbara Eichhorst, Kirsten Fischer, Michael Hallek, Othman Al-Sawaf
Journal: Blood
Blood (2021) 138 (Supplement 1): 1552.
https://doi.org/10.1182/blood-2021-150698
Published: 2021